Anaphylaxis Treatment Global Market Demand Analysis, Manufacturers Share, Regions, Risk Analysis, Driving Forces and Application, Forecast To 2033

The anaphylaxis treatment market size has grown strongly in recent years. It will grow from $5.73 billion in 2023 to $6.15 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing incidence of allergic reactions, wider recognition of anaphylaxis, increased availability of epinephrine auto-injectors, public awareness and education, healthcare professional training.

The anaphylaxis treatment market size is expected to see strong growth in the next few years. It will grow to $7.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to innovation in biologic therapies, customized treatment approaches, global efforts on food safety, patient empowerment and advocacy, enhanced emergency medical services. Major trends in the forecast period include auto-injectors innovation, telemedicine for anaphylaxis management, improved allergen immunotherapy, biometric wearables for allergen detection, collaborations in allergy research.

Market Overview -
Anaphylaxis treatment refers to the treatment of life-threatening allergic reactions to foods, insect stings, medications, and latex in which immediate administration of epinephrine is given to reverse the allergic reaction and stabilize the patient's condition. Rapid medical treatment and comprehensive supportive care are required to effectively manage potentially life-threatening symptoms of anaphylaxis.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12105&type=smp

Surging Prevalence Of Food Allergies Sparks Accelerated Growth In The Anaphylaxis Treatment Market
The rise in the prevalence of food allergies is expected to propel the growth of the anaphylaxis treatment market going forward. Food allergy refers to an immune reaction to proteins in food. Anaphylaxis treatment helps to prevent the progression of life-threatening allergic symptoms involving the skin, mucosal surface, respiratory compromise, hypotension, and end-organ dysfunction. For instance, in January 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2021, 31.8% of adults aged 18 and older reported having eczema, a seasonal allergy, or a food allergy. One-fourth (25.7%) of adults had a seasonal allergy, 6.2% had a food allergy, and 7.3% of individuals had eczema. Therefore, the rise in the prevalence of food allergies is driving the growth of the anaphylaxis treatment market.

Competitive Landscape -
Major companies operating in the anaphylaxis treatment market report are Pfizer Inc., Merck & Co. Inc., Novartis International AG, Abbott Laboratories, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Bausch Health Companies, Sun Pharmaceutical Industries Ltd., Perrigo Co, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals Inc., ALK-Abelló A/S, Amphastar Pharmaceuticals Inc., Par Pharmaceutical Inc., Genentech Inc., MannKind Corporation, Meridian Medical Technologies LLC, Aquestive Therapeutics Inc., Sandoz Inc., Bioprojet SCR, Adamis Pharmaceutical Corporation, Impax Laboratories LLC.

Advancements In Anaphylaxis Treatment Products Shape Market Dynamics
Advancement in product development is a key trend gaining popularity in the anaphylaxis treatment market. Major companies operating in the anaphylaxis treatment market are advancing their products to sustain their position in the market. For instance, in April 2022, Aquestive Therapeutics Inc., a US-based pharmaceutical company, received Fast Track designation for AQST-109 for the treatment of severe allergic responses, including anaphylaxis, from the Food and Drug Administration. Aquestive is moving forward with the clinical testing of AQST-109, the first and only orally administered epinephrine product candidate that has demonstrated clinical outcomes equivalent to autoinjectors (such as EpiPen and Auvi-Q) for the treatment of allergic emergencies, including anaphylaxis.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/anaphylaxis-treatment-global-market-report

Key Segments -
The anaphylaxis treatment market covered in this report is segmented -
1) By Treatment: Epinephrine, Antihistamines, Steroids, Beta-antagonists, Other Treatments
2) By Product: Tablets, Capsules, Other Products
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By Application: Food Allergy, Pollen Allergy, Dust Mites Allergy, Other Applications

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.